IMNN Earnings — Imunon, Inc. Common Stock Post-ER Performance | BigEarnings
IMNN — Imunon, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$2.30
Market Cap$9.7M
P/E—
52W Range$2.08 – $41.22
Next Earnings2026-08-04
About Imunon, Inc. Common Stock
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
